Venturi Wealth Management LLC Has $1.70 Million Position in Abbott Laboratories $ABT

Venturi Wealth Management LLC cut its position in shares of Abbott Laboratories (NYSE:ABT) by 28.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 16,588 shares of the healthcare product maker’s stock after selling 6,528 shares during the period. Venturi Wealth Management LLC’s holdings in Abbott Laboratories were worth $1,703,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of ABT. Freemont Management S.A. grew its stake in Abbott Laboratories by 197.2% in the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock valued at $1,341,000 after buying an additional 7,100 shares during the last quarter. PFA Pension Forsikringsaktieselskab acquired a new stake in Abbott Laboratories during the fourth quarter worth approximately $116,580,000. Thrivent Financial for Lutherans boosted its holdings in shares of Abbott Laboratories by 24.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock worth $30,931,000 after acquiring an additional 48,286 shares during the period. Danica Pension Livsforsikringsaktieselskab acquired a new position in shares of Abbott Laboratories in the third quarter valued at approximately $185,640,000. Finally, Net Worth Advisory Group bought a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $1,366,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ABT has been the subject of several recent research reports. Weiss Ratings downgraded Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, June 16th. Argus lowered their price objective on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, April 21st. Citigroup reduced their target price on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Evercore cut their price objective on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Finally, TD Cowen decreased their target price on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $118.30.

Insiders Place Their Bets

In other news, CFO Philip P. Boudreau acquired 2,200 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The shares were bought at an average price of $91.50 per share, with a total value of $201,300.00. Following the acquisition, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. The trade was a ? increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction on Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the acquisition, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $94.02 on Friday. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The stock’s 50-day simple moving average is $89.08 and its 200 day simple moving average is $105.38. The firm has a market capitalization of $163.77 billion, a PE ratio of 26.34, a price-to-earnings-growth ratio of 1.62 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter in the previous year, the firm earned $1.09 earnings per share. The business’s quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.7%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 70.59%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.